List view / Grid view

Opdivo (nivolumab)

Filter the results



N is for Nivolumab

1 December 2016 | By Niamh Louise Marriott, Digital Editor

N is for Nivolumab - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...


SMC ‘U-turn’ offers lifeline to Scottish skin cancer patients

8 August 2016 | By Bristol-Myers Squibb

The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access…


Bristol-Myers Squibb, Pharmacyclics and Janssen announce clinical collaboration to evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in non-Hodgkin lymphoma

13 October 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (NYSE:BMY), Pharmacyclics, Inc. (NASDAQ:PCYC), and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO® (nivolumab) in combination with IMBRUVICA® (ibrutinib), an oral Bruton's…